- Home
- NRIX vs AEVA Comparison
NRIX vs AEVA Comparison
Compare NRIX & AEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- AEVA
- Stock Information
- Founded
- NRIX 2009
- AEVA 2019
- Country
- NRIX United States
- AEVA United States
- Employees
- NRIX N/A
- AEVA N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- AEVA Auto Parts:O.E.M.
- Sector
- NRIX Health Care
- AEVA Consumer Discretionary
- Exchange
- NRIX Nasdaq
- AEVA Nasdaq
- Market Cap
- NRIX 766.0M
- AEVA 808.6M
- IPO Year
- NRIX 2020
- AEVA N/A
- Fundamental
- Price
- NRIX $10.56
- AEVA $13.28
- Analyst Decision
- NRIX Strong Buy
- AEVA Strong Buy
- Analyst Count
- NRIX 15
- AEVA 5
- Target Price
- NRIX $29.13
- AEVA $20.80
- AVG Volume (30 Days)
- NRIX 678.5K
- AEVA 2.8M
- Earning Date
- NRIX 10-10-2025
- AEVA 07-31-2025
- Dividend Yield
- NRIX N/A
- AEVA N/A
- EPS Growth
- NRIX N/A
- AEVA N/A
- EPS
- NRIX N/A
- AEVA N/A
- Revenue
- NRIX $88,381,000.00
- AEVA $13,825,000.00
- Revenue This Year
- NRIX $71.51
- AEVA $94.59
- Revenue Next Year
- NRIX N/A
- AEVA $127.05
- P/E Ratio
- NRIX N/A
- AEVA N/A
- Revenue Growth
- NRIX 41.86
- AEVA 111.39
- 52 Week Low
- NRIX $8.18
- AEVA $2.36
- 52 Week High
- NRIX $29.56
- AEVA $38.80
- Technical
- Relative Strength Index (RSI)
- NRIX 43.38
- AEVA 31.01
- Support Level
- NRIX $9.44
- AEVA $12.45
- Resistance Level
- NRIX $10.98
- AEVA $14.60
- Average True Range (ATR)
- NRIX 0.57
- AEVA 1.72
- MACD
- NRIX -0.08
- AEVA -0.41
- Stochastic Oscillator
- NRIX 38.75
- AEVA 8.97
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.